Derma Sciences Prices Offering, Pfizer Partners with Protalix: Healthcare Business Wrap

In a Thursday press release, Derma Sciences (NASDAQ:DSCI) announced the pricing of an underwritten public offering of 3.062 million shares of common stock to the public at $10.34 per share. The firm grants the underwriters a 30-day option to acquire  an additional 459,300 shares of common stock to cover any over-allotments. The offering should close on or about December 11th, subject to the usual closing conditions.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

MiMedx Group (MDXG.PK) announced Wednesday that it has received its first issued patent linked to tissue grafts derived from the placenta; the patent relates to the AmnioFix brand allografts. The firm is an integrated developer, maker and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

Pfizer (NYSE:PFE) and Protalix BioTherapeutics (AMEX:PLX) have entered into a Clinical Development Agreement through which Protalix will continue to administer, manage, and sponsor current, ongoing clinical trials involving Elelyso. The latter currently sponsors adult and pediatric extension evaluations of Elelyso, but new clinical trials for the drug will be conducted and sponsored by Pfizer. Through the terms of the arrangement, Protalix is eligible to receive a milestone payment of $8.3 million upon the attainment of specific near-term clinical development milestones.

Don’t Miss: Pharmaceuticals: EU Courts Lay Down the Law.